Carine Poussin, Bjoern Titz, Yang Xiang, Laurel Baglia, Rachel Berg, David Bornand, Mohammed-Amin Choukrallah, Timothy Curran, Sophie Dijon, Eric Dossin, Remi Dulize, Doris Etter, Maria Fatarova, Loyse Felber Medlin, Adrian Haiduc, Edina Kishazi, Aditya R Kolli, Athanasios Kondylis, Emmanuel Kottelat, Csaba Laszlo, Oksana Lavrynenko, Yvan Eb-Levadoux, Catherine Nury, Dariusz Peric, Melissa Rizza, Thomas Schneider, Emmanuel Guedj, Florian Calvino, Nicolas Sierro, Philippe Guy, Nikolai V Ivanov, Patrick Picavet, Sherry Spinelli, Julia Hoeng, Manuel C Peitsch
Cigarette smoking is a major preventable cause of morbidity and mortality. While quitting smoking is the best option, switching from cigarettes to non-combustible alternatives (NCAs) such as e-vapor products is a viable harm reduction approach for smokers who would otherwise continue to smoke. A key challenge for the clinical assessment of NCAs is that self-reported product use can be unreliable, compromising the proper evaluation of their risk reduction potential. In this cross-sectional study of 205 healthy volunteers, we combined comprehensive exposure characterization with in-depth multi-omics profiling to compare effects across four study groups: cigarette smokers (CS), e-vapor users (EV), former smokers (FS), and never smokers (NS)...
February 21, 2024: Scientific Reports